NCT05639153View on ClinicalTrials.gov

A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Malignant Neoplasm of Digestive System
Interventions
DRUG

DR30303

DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.

Trial Locations (1)

311100

RECRUITING

Sir Run Run Shaw Hospital，Zhejiang University School of Medicine, Hanzhou

All Listed Sponsors
lead

Zhejiang Doer Biologics Co., Ltd.

INDUSTRY